RET oncogene | sciencenewsnet.in

Breaking News

Waste oil to wonder material: transforming trash into supercapacitor gold

AI-enhanced satellite carbon monoxide fast retrieval

Harnessing nature’s arsenal: phospholipids in plant defense mechanisms

The fintech effect: boosting India’s digital economy into the fast lane

KIER Unveils Catalyst Innovations for Sustainable Turquoise Hydrogen Solutions

How HIV Research Reshaped Modern Medicine

Chula Presents “Mud Sang,” a Documentary Film to Revive the Spirit of Muay Thai in the World Arena

Coastal revelations from space: new satellite tech maps sandy beaches

Sharing is Caring: Central Europe’s First Farmers Lived in Equality

A New Approach to Predicting Malaria Drug Resistance

29 Nov, 2024

Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations

June 9, 2021 sarah JonasResearch Results

Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.